Search for a trial

A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer

To investigate disease control after nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer.

Lanorec study: Lateral Nodal Recurrence in rectal Cancer

To investigate whether a standardized multidisciplinary treatment of rectal cancer patients with enlarged lateral lymph nodes will decrease the amount of local recurrences. Secondary outcomes are morbidity, quality of life and functional outcomes.

PANcreatic Cancer lOcalized disease in frail or elderly patients unfit for both chemotherapy and surgery treated with Stereotactic Ablative Radiotherapy (PANCOSAR): a multicenter randomized controlled trial

The main goal of the current randomized study is to investigate if SABR may relieve tumor-related symptoms, improve the quality of life and potentially prolong survival in this frail patient group compared to best supportive care, which is the…

A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select druk combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer.

Primary objective:To characterize safety and tolerability of each treatment arm tested and identify recommended doses (RD) and regimens for future studies, by assessing the incidence and severity of AEs and SAEs; including changes in laboratory…

*Evaluating the feasibility of intraluminal oxygen administration at the site of the anastomosis in patients who underwent an esophagectomy; a pilot study*

To explore feasibility of intraluminal oxygen administration at the site of the anastomosis in patients who underwent an esophagectomy.

TGF-β And PDL-1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY)

This study has been transitioned to CTIS with ID 2023-503312-32-00 check the CTIS register for the current data. Possibly, outcomes of treatment of irresectable squamous cell carcinoma of the esophagus can be improved by adding bintrafusp alfa to…

An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy

To demonstrate the superiority of S 95005 + bevacizumab over capecitabine + bevacizumab in terms of Progression-free survival (PFS) based on Investigator assessment in first-line treatment of patients with unresectable metastatic colorectal cancer…

A prospective, randomised, controlled, open-label, multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

This study has been transitioned to CTIS with ID 2023-510444-21-00 check the CTIS register for the current data. The primary objective is to demonstrate the efficacy of Peptide Receptor Radionuclide Therapy with 177Lu-edotreotide to prolong…

A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants with Familial Adenomatous Polyposis

The purpose of this study is to determine the effect of JNJ-64251330 in participants with Familial Adenomatous Polyposis(FAP) on colorectal polyp burden (sum of the polyp diameters).

A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with advanced and metastatic gastrointestinal cancer

Main objective:English To determine the antitumor activity of SAR444245 in combination with other anticancer therapiesSecondary objectives: English - To assess the safety of SAR444245 when combined with other anticancer therapies- To assess other…

Phase I/Ib study with the combination of RMC-4630 and LY3214996 in metastatic KRAS mutant CRC, PDAC and NSCLC - The SHERPA-trial

Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…

A multicenter phase II randomized trial to evaluate systemic therapy versus systemic therapy in combination with stereotactic radiotherapy in patients with metastatic colorectal cancer

To assess the impact of SBRT in combination with systemic therapy compared to systemic therapy alone on safety and efficacy in patients with mCRC.

DETECT: DEfining the Target volume for Endoluminal radiation boosting in patients with reCTal cancer

Primary objectiveTo determine the maximum distance of microscopic tumor spread per patient in all directions from the macroscopic tumor remnant in the pathology specimen.Main secondary objectives- To determine the maximum distance of microscopic…

Pilot study to determine the intraTUMORal OsImertinib concentration in patients with peritoneal metastasizeD colorectal cancer (TUMOROID study)

The main objective of this pilot study is to determine the intratumoral concentrations of osimertinib upon 1 week of treatment in peritoneal metastasis of patients who are candidate for CRS-HIPEC treatment (group 1) and in liver metastasis of…

Neoadjuvant treatment in rectal cancer with radiotherapy followed by atezolizumab and bevacizumab (TARZAN-trial)

This study has been transitioned to CTIS with ID 2024-517119-59-00 check the CTIS register for the current data. *- To explore efficacy of neoadjuvant atezolizumab and bevacizumab following radiotherapy in low- to intermediate-risk rectal cancer• To…

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Primary• To evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first line treatment) as measured by Progression Free Survival (PFS) in subjects with Claudin (CLDN) 18.2-positive,…

Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis

To explore the effect of treatment with guselkumab in subjects with Familial Adenomatous Polyposis (FAP) on rectal/pouch polyp burden (the sum of the polyp diameters)

ULTRA-ERAS: discharge after 24hours after colorectal surgery, a pilot study

The aim of the study is to assess if hospitalization can be reduced with the use of an early discharge protocol, named *ULTRA-ERAS*, in combination with tele monitoring in patients in elective colorectal surgery

Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases. CAIRO5 a randomized phase 3 study of the Dutch Colorectal Cancer Group (DCCG)

To determine the median progression-free survival (PFS) and R0/1 secondary resection rate upon induction systemic treatment in colorectal cancer patients with initially unresectable liver-only metastases, stratified by RAS and BRAF tumor mutation…

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)

This study has been transitioned to CTIS with ID 2023-510319-20-00 check the CTIS register for the current data. Primary objective:- To compare the efficacy of zanidatamab in combination with chemotherapy or in combination with chemotherapy and…